Medivation (MDVN) and Pfizer (PFE) will discontinue development of dimebon for all indications and will terminate the ongoing open label extension study in Alzheimer’s disease. The companies also announce that they will terminate their collaboration to co-develop and market dimebon pursuant to the terms of their Collaboration Agreement.
Read More on the Alzheimer's Reading Room -- Alzheimer's Drug Dimebon (Medivation) Fails, Sad Day
This brings the number of consecutive failed clinical trials for Alzheimer's medications to 15.
No comments:
Post a Comment